Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of “Hold” from Analysts

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has received an average recommendation of “Hold” from the eight brokerages that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $45.25.

Several analysts recently commented on ENTA shares. JMP Securities raised their price objective on Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Royal Bank of Canada reaffirmed a “buy” rating and set a $54.00 price objective on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. Finally, TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday, December 13th.

Enanta Pharmaceuticals (NASDAQ:ENTA) traded up $4.10 during mid-day trading on Friday, hitting $78.32. The stock had a trading volume of 199,196 shares, compared to its average volume of 141,096. The firm has a market cap of $1,421.42, a P/E ratio of 89.00 and a beta of 0.64. Enanta Pharmaceuticals has a one year low of $25.92 and a one year high of $78.35.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). The business had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business’s quarterly revenue was up 491.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.09) EPS. equities analysts forecast that Enanta Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $220,000. Hartland & Co. LLC bought a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $237,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of Enanta Pharmaceuticals by 63.7% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 5,370 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 2,090 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Enanta Pharmaceuticals by 30.0% in the 3rd quarter. SG Americas Securities LLC now owns 5,662 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 1,308 shares in the last quarter. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $289,000. 66.89% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/27/enanta-pharmaceuticals-inc-enta-receives-average-rating-of-hold-from-analysts.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply